Filing Flows › BeOne Medicines (ONC) › R&D spending
BeOne Medicines (ONC) R&D spending by quarter
BeOne Medicines' R&D spending was $661M in Q3 2026 (third quarter 2026), +8% from Q2 2026. Over the last 7 quarters it ranged from $482M (Q1 2025) to $661M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $661M | +8% | +26% |
| Q2 2026 | $612M | +13% | +17% |
| Q1 2026 | $541M | -12% | +12% |
| Q4 2025 | $615M | +18% | — |
| Q3 2025 | $524M | -0.2% | — |
| Q2 2025 | $525M | +9% | — |
| Q1 2025 | $482M | — | — |
Q3 2026 at a glance
BeOne Medicines, Q3 2026: revenue $1.9B (+34% year over year), operating margin 22.2%, net earnings $385M, operating cash flow $509M. The chart follows the revenue to costs, profit and cash.
Questions
What is BeOne Medicines' R&D spending?
BeOne Medicines' R&D spending was $661M in Q3 2026 (third quarter 2026), +8% from Q2 2026.
How has BeOne Medicines' R&D spending changed?
Over the last 7 quarters it ranged from $482M (Q1 2025) to $661M (Q3 2026).